Highly specific inhibition of C1q globular-head binding to human IgG: A novel approach to control and regulate the classical complement pathway using an engineered single chain antibody variable fragment

Molecular Immunology

Volumn 45, Issue 9, 2008, Pages 2570-2580

  Hwang, Hee Young ^a   Duvall, Marcus R ^a   Tomlinson, Stephen ^a   Boackle, Robert J ^a,b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Alzheimer's disease; Arthritis; C1; C1q; C1q globular heads; C4; Classical complement pathway; Complement; IgG; Inflammation; Inflammatory diseases; scFv

Indexed keywords

COMPLEMENT COMPONENT C1Q; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1 ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

ANTIBODY ENGINEERING; ARTICLE; COMPLEMENT CLASSICAL PATHWAY; CONTROLLED STUDY; DRUG INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; HEAVY CHAIN; HOST; HUMAN; HUMAN CELL; HYBRIDOMA; LIGHT CHAIN; LIQUID; MICROTITER PLATE ASSAY; PHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN INTERACTION; PROTEIN PURIFICATION; REGULATORY MECHANISM; SERUM; TISSUE INJURY;

COMPLEMENT C1Q; COMPLEMENT PATHWAY, CLASSICAL; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN VARIABLE REGION; PROTEIN ENGINEERING; RECOMBINANT FUSION PROTEINS;

EID: 40849125355     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2007.12.019     Document Type: Article

References (45)

1. Arumugam T.V., Tang S.C., Lathia J.D., Cheng A., Mughal M.R., Chigurupati S., Magnus T., Chan S.L., Jo D.G., Ouyang X., Fairlie D.P., Granger D.N., Vortmeyer A., Basta M., and Mattson M.P. Intravenous immunoglobulin (IVIG) protects the brain against experimental stroke by preventing complement-mediated neuronal cell death. Proc. Natl. Acad. Sci. U.S.A. 104 (2007) 14104-14109
2. Boackle R.J., Connor M.H., and Vesely J. High molecular weight non-immunoglobulin salivary agglutinins (NIA) bind C1Q globular heads and have the potential to activate the first complement component. Mol. Immunol. 30 (1993) 309-319
3. Boackle R.J., Johnson B.J., and Caughman G.B. An IgG primary sequence exposure theory for complement activation using synthetic peptides. Nature 282 (1979) 742-743
4. Boackle R.J., Nguyen Q.L., Leite R.S., Yang X., and Vesely J. Complement-coated antibody-transfer (CCAT); serum IgA1 antibodies intercept and transport C4 and C3 fragments and preserve IgG1 deployment (PGD). Mol. Immunol. 43 (2006) 236-245
5. Bobak D.A., Gaither T.A., Frank M.M., and Tenner A.J. Modulation of FcR function by complement: subcomponent C1q enhances the phagocytosis of IgG-opsonized targets by human monocytes and culture-derived macrophages. J. Immunol. 138 (1987) 1150-1156
6. Bradt B.M., Kolb W.P., and Cooper N.R. Complement-dependent proinflammatory properties of the Alzheimer's disease beta-peptide. J. Exp. Med. 188 (1998) 431-438
7. Bristow C.L., and Boackle R.J. Evidence for the binding of human serum amyloid P component to Clq and Fab gamma. Mol. Immunol. 23 (1986) 1045-1052
8. Bureeva S., Andia-Pravdivy J., Symon A., Bichucher A., Moskaleva V., Popenko V., Shpak A., Shvets V., Kozlov L., and Kaplun A. Selective inhibition of the interaction of C1q with immunoglobulins and the classical pathway of complement activation by steroids and triterpenoids sulfates. Bioorg. Med. Chem. 15 (2007) 3489-3498
9. Chen C.H., and Boackle R.J. A newly discovered function for C1 inhibitor, removal of the entire C1qr2s2 complex from immobilized human IgG subclasses. Clin. Immunol. Immunopathol. 87 (1998) 68-74
10. Chen C.H., Lam C.F., and Boackle R.J. C1 inhibitor removes the entire C1qr2s2 complex from anti-C1Q monoclonal antibodies with low binding affinities. Immunology 95 (1998) 648-654
11. Cooper N. The classical complement pathway: activation and regulation of the first complement component. Adv. Immunol. (1985) 65
12. Daha M.R., Klar N., Hoekzema R., and van Es L.A. Enhanced Ig production by human peripheral lymphocytes induced by aggregated C1q. J. Immunol. 144 (1990) 1227-1232
13. Edelson B.T., Stricker T.P., Li Z., Dickeson S.K., Shepherd V.L., Santoro S.A., and Zutter M.M. Novel collectin/C1q receptor mediates mast cell activation and innate immunity. Blood 107 (2006) 143-150
14. Farady C.J., Sun J., Darragh M.R., Miller S.M., and Craik C.S. The mechanism of inhibition of antibody-based inhibitors of membrane-type serine protease 1 (MT-SP1). J. Mol. Biol. 369 (2007) 1041-1051
15. Fraser D.A., Arora M., Bohlson S.S., Lozano E., and Tenner A.J. Generation of inhibitory NFkappaB complexes and phosphorylated cAMP response element-binding protein correlates with the anti-inflammatory activity of complement protein C1q in human monocytes. J. Biol. Chem. 282 (2007) 7360-7367
16. Gaboriaud C., Juanhuix J., Gruez A., Lacroix M., Darnault C., Pignol D., Verger D., Fontecilla-Camps J.C., and Arlaud G.J. The crystal structure of the globular head of complement protein C1q provides a basis for its versatile recognition properties. J. Biol. Chem. 278 (2003) 46974-46982
17. Gething M.J., and Sambrook J. Protein folding in the cell. Nature 355 (1992) 33-45
18. Goodwin J.L., Uemura E., and Cunnick J.E. Microglial release of nitric oxide by the synergistic action of beta-amyloid and IFN-gamma. Brain Res. 692 (1995) 207-214
19. Guan E., Robinson S.L., Goodman E.B., and Tenner A.J. Cell-surface protein identified on phagocytic cells modulates the C1q-mediated enhancement of phagocytosis. J. Immunol. 152 (1994) 4005-4016
20. Kishore U., Gupta S.K., Perdikoulis M.V., Kojouharova M.S., Urban B.C., and Reid K.B. Modular organization of the carboxyl-terminal, globular head region of human C1q A, B, and C chains. J. Immunol. 171 (2003) 812-820
21. Kishore U., and Reid K.B. Modular organization of proteins containing C1q-like globular domain. Immunopharmacology 42 (1999) 15-21
22. Knackmuss S., Krause S., Engel K., Reusch U., Virchow J.C., Mueller T., Kraich M., Little M., Luttmann W., and Friedrich K. Specific inhibition of interleukin-13 activity by a recombinant human single-chain immunoglobulin domain directed against the IL-13 receptor alpha1 chain. Biol. Chem. 388 (2007) 325-330
23. Kovacsovics T., Tschopp J., Kress A., and Isliker H. Antibody-independent activation of C1, the first component of complement, by cardiolipin. J. Immunol. 135 (1985) 2695-2700
24. Kozak M. Possible role of flanking nucleotides in recognition of the AUG initiator codon by eukaryotic ribosomes. Nucl. Acids Res. 9 (1981) 5233-5252
25. Krumdieck R., Hook M., Rosenberg L.C., and Volanakis J.E. The proteoglycan decorin binds C1q and inhibits the activity of the C1 complex. J. Immunol. 149 (1992) 3695-3701
26. Kubetzko S., Balic E., Waibel R., Zangemeister-Wittke U., and Plückthun A. PEGylation and multimerization of the anti-p185HER-2 single chain Fv fragment 4D5: effects on tumor targeting. J. Biol. Chem. 281 (2006) 35186-35201
27. Padilla N.D., van Vliet A.K., Schoots I.G., Seron M.V., Maas M.A., Peltenburg E.E., de Vries A., Niessen H.W., Hack C.E., and van Gulik T.M. C-reactive protein and natural IgM antibodies are activators of complement in a rat model of intestinal ischemia and reperfusion. Surgery 142 (2007) 722-733
28. Porter R.R., and Reid K.B. Activation of the complement system by antibody-antigen complexes: the classical pathway. Adv. Protein Chem. 33 (1979) 1-71
29. Reid K.B., and Porter R.R. Subunit composition and structure of subcomponent C1q of the first component of human complement. Biochem. J. 155 (1976) 19-23
30. Rozanov D.V., Savinov A.Y., Golubkov V.S., Postnova T.I., Remacle A., Tomlinson S., and Strongin A.Y. Cellular membrane type-1 matrix metalloproteinase (MT1-MMP) cleaves C3b, an essential component of the complement system. J. Biol. Chem. 279 (2004) 46551-46557
31. Ruiz S., Henschen-Edman A.H., and Tenner A.J. Localization of the site on the complement component C1q required for the stimulation of neutrophil superoxide production. J. Biol. Chem. 270 (1995) 30627-30634
32. Saad A.F., Virella G., Chassereau C., Boackle R.J., and Lopes-Virella M.F. Autoimmune OxLDL immune-complexes activate the classical pathway of complement and induce cytokine production by mono mac 6 cells and primary human macrophages. J. Lipid Res. 47 (2006) 1975-1983
33. Sarvari M., Vago I., Weber C.S., Nagy J., Gal P., Mak M., Kosa J.P., Zavodszky P., and Pazmany T. Inhibition of C1q-beta-amyloid binding protects hippocampal cells against complement mediated toxicity. J. Neuroimmunol. 137 (2003) 12-18
34. Schumaker V.N., Hanson D.C., Kilchherr E., Phillips M.L., and Poon P.H. A molecular mechanism for the activation of the first component of complement by immune complexes. Mol. Immunol. 23 (1986) 557-565
35. Selkoe D.J., and Schenk D. Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Annu. Rev. Pharmacol. Toxicol. 43 (2003) 545-584
36. Sellar G., Cockburn D., and Reid K.B. Localization of the gene cluster encoding the A, B, and C chains of human C1q to 1p34-1-1p36.3. Immunogenetics 35 (1992) 3
37. Széplaki G., Varga L., Laki J., Dósa E., Rugonfalvi-Kiss S., Madsen H.O., Prohászka Z., Kocsis A., Gál P., Szabó A., Acsády G., Karádi I., Selmeci L., Garred P., Füst G., and Entz L. Low c1-inhibitor levels predict early restenosis after eversion carotid endarterectomy. Arterioscler. Thromb. Vasc. Biol. 27 (2007) 2756-2762
38. Uwatoko S., and Mannik M. The location of binding sites on C1q for DNA. J. Immunol. 144 (1990) 3484-3488
39. van den Berg R.H., Faber-Krol M.C., Sim R.B., and Daha M.R. The first subcomponent of complement, C1q, triggers the production of IL-8, IL-6, and monocyte chemoattractant peptide-1 by human umbilical vein endothelial cells. J. Immunol. 161 (1998) 6924-6930
40. Webster S.D., Yang A.J., Margol L., Garzon-Rodriguez W., Glabe C.G., and Tenner A.J. Complement component C1q modulates the phagocytosis of Abeta by microglia. Exp. Neurol. 161 (2000) 127-138
41. Ying S.C., Gewurz A.T., Jiang H., and Gewurz H. Human serum amyloid P component oligomers bind and activate the classical complement pathway via residues 14-26 and 76-92 of the A chain collagen-like region of C1q. J. Immunol. 150 (1993) 169-176
42. Yonemasu K., and Stroud R.M. Structural studies on human Clq: non-covalent and covalent subunits. Immunochemistry 9 (1972) 545-554
43. Young Jr. K.R., Ambrus Jr. J.L., Malbran A., Fauci A.S., and Tenner A.J. Complement subcomponent C1q stimulates Ig production by human B lymphocytes. J. Immunol. 146 (1991) 3356-3364
44. Zhang J., Wright W., Bernlohr D.A., Cushman S.W., and Chen X. Alterations of the classic pathway of complement in adipose tissue of obesity and insulin resistance. Am. J. Physiol. Endocrinol. Metab. 292 (2007) E1433-E1440
45. Ziccardi R.J., and Cooper N.R. Active disassembly of the first complement component, C-1, by C-1 inactivator. J. Immunol. 123 (1979) 788-792